Publicaciones en colaboración con investigadores/as de Hospital Universitario de Cruces (36)

2024

  1. Sphingosine 1-phosphate receptor subtype 1 (S1P1) activity in the course of Alzheimer's disease

    Neurobiology of Disease, Vol. 202

2019

  1. Myocardial MIBG scintigraphy in genetic Parkinson’s disease as a model for Lewy body disorders

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 46, Núm. 2, pp. 376-384

2017

  1. Group-level progressive alterations in brain connectivity patterns revealed by diffusion-tensor brain networks across severity stages in Alzheimer's disease

    Frontiers in Aging Neuroscience, Vol. 9, Núm. JUL

2016

  1. A study using positron emission tomography of a case of vascular dementia due to left thalamic haematoma, an example of the diaschisis phenomenon

    Revista de Neurologia, Vol. 62, Núm. 9, pp. 408-410

  2. Dysexecutive syndrome in amnesic mild cognitive impairment: A multicenter study

    BMC Neurology, Vol. 16, Núm. 1

  3. Iowa APP mutation-related hereditary cerebral amyloid angiopathy (CAA): A new family from Spain

    Journal of the Neurological Sciences

  4. Knowledge and Attitudes of Nurses in Spain about Inhaled Therapy: Results of a National Survey

    Journal of Aerosol Medicine and Pulmonary Drug Delivery, Vol. 29, Núm. 1, pp. 86-93

  5. Linfomatosis meníngea como recidiva tardía de macroglobulinemia de Waldenström

    Medicina Clinica

  6. One-Year reference norms of cognitive change in Spanish old adults: Data from the NEURONORMA Sample

    Archives of Clinical Neuropsychology, Vol. 31, Núm. 4, pp. 378-388

2015

  1. Autonomic involvement in Parkinsonian carriers of PARK2 gene mutations

    Parkinsonism and Related Disorders, Vol. 21, Núm. 7, pp. 717-722

  2. Cognitive and behavioral symptoms in Parkinson's disease patients with the G2019S and R1441G mutations of the LRRK2 gene

    Parkinsonism and Related Disorders, Vol. 21, Núm. 5, pp. 494-499

2014

  1. Diagnostic validity of the alzheimer's disease functional assessment and change scale in mild cognitive impairment and mild to moderate alzheimer's disease

    Dementia and Geriatric Cognitive Disorders, Vol. 37, Núm. 5-6, pp. 366-375

  2. Spanish multicenter normative studies (NEURONORMA project): Normative data and equivalence of four BNT short-form versions

    Archives of Clinical Neuropsychology, Vol. 29, Núm. 1, pp. 60-74

2013

  1. Neuropsychiatric symptoms in amnestic mild cognitive impairment: Increased risk and faster progression to dementia

    Current Alzheimer Research, Vol. 10, Núm. 1, pp. 86-94

2012

  1. Effect of synthetic cannabinoid CB1 agonist (WIN 55212-2) and antagonist (AM 251) on intraocular pressure in rats

    Glaucoma: Etiology, Pathogenesis and Treatments (Nova Science Publishers, Inc.), pp. 147-156

  2. Using artificial neural networks in clinical neuropsychology: High performance in mild cognitive impairment and Alzheimer's disease

    Journal of Clinical and Experimental Neuropsychology, Vol. 34, Núm. 2, pp. 195-208

2011

  1. Prevalence and European comparison of dementia in a ≥75-year-old composite population in Spain

    Acta Neurologica Scandinavica, Vol. 123, Núm. 5, pp. 316-324

  2. Spanish multicenter normative studies (neuronorma project): Norms for the abbreviated barcelona test

    Archives of Clinical Neuropsychology, Vol. 26, Núm. 2, pp. 144-157

2010

  1. Behavioural symptoms in patients with Alzheimer's disease and their association with cognitive impairment

    BMC Neurology, Vol. 10

  2. Prevalence of neuropsychiatric symptoms in mild cognitive impairment and Alzheimer's disease, and its relationship with cognitive impairment

    Current Alzheimer Research, Vol. 7, Núm. 6, pp. 517-526